Download Files:
Moxisylyte (hydrochloride)
SKU
HY-B1435-1 g
Category Reference compound
Tags Adrenergic Receptor, Cardiovascular Disease; Endocrinology, GPCR/G Protein;Neuronal Signaling
$60 – $72
Web ID
– HY-B1435
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C16H26ClNO3
References
– [1]Ryuji Sakakibara et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. 2000, March, 15, Pages 191-195.|[2]Marquer C et al. Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use inimpotence. Fundam Clin Pharmacol, 1998, 12(4):377-87.
CAS Number
– 964-52-3
Molecular Weight
– 315.84
Compound Purity
– 99.96
SMILES
– CC(C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1)C.[H]Cl
Clinical Information
– Launched
Research Area
– Cardiovascular Disease; Endocrinology
Solubility
– DMSO : 20 mg/mL (ultrasonic)|H2O : ≥ 50 mg/mL
Target
– Adrenergic Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.